Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

AstraZeneca Seeking to Get Cancer Drugs to Patients Early

AstraZeneca Seeking to Get Cancer Drugs to Patients Early | Lung Cancer Dispatch | Scoop.it

"British patients could benefit from AstraZeneca's promising new cancer drugs well before they complete clinical testing, the Telegraph can reveal.


"Pascal Soriot, chief executive, told the Telegraph he was looking to make two of Astra's most eye-catching cancer drugs widely available to patients as soon as possible.


"Britain's recently launched early access to medicines scheme, which aims to get drugs to patients years earlier than the normal regulatory process allows, is among the programmes in Mr Soriot's sights. The US, France and Japan have also established pathways to fast-track promising new drugs to patients ahead of final regulatory approval."

Cancer Commons's insight:

The Telegraph  |  Jun 2, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Funding Strategy Needed to Support EGFR Mutation Testing in Canada

Funding Strategy Needed to Support EGFR Mutation Testing in Canada | Lung Cancer Dispatch | Scoop.it

Funding represents a decisive barrier to the nationwide implementation of genetic testing for a key lung cancer mutation in Canada, a recent study finds. Patients with non-small cell lung cancer (NSCLC) who have a mutation in the EGFR gene frequently benefit from treatment with EGFR inhibitors. AstraZeneca, makers of the EGFR inhibitor gefinitinb (Iressa), reimbursed Canadian laboratories for offering EGFR mutation testing to patients with advanced non-squamous NSCLC for 12 months. EGFR mutation testing was rapidly adopted into routine clinical practice in Canada. However, testing rates dropped sharply once the reimbursement program ended. Researchers conclude that a national strategy is needed to provide resources for continued EGFR testing.

Cancer Commons's insight:

Medical Xpress | Jul 25, 2013

more...
No comment yet.